Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Cancan Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0485-4030; OpenAlex author ID A5088613739. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 9 papers · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 28

  1. Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain h… Co-author DOI 10.1007/s10238-025-01969-5↗
  2. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  3. Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin. Co-author DOI 10.18332/tid/203455↗
  4. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis. Last author DOI 10.1016/j.cellsig.2024.111381↗
  5. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215976↗
  6. An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer. First author DOI 10.3389/fgene.2023.1084275↗
  7. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  8. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Co-author DOI 10.3389/fgene.2022.940794↗
  9. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.03.015↗
  10. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  11. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  12. Huaier extract restrains pancreatic cancer by suppressing Wnt/β-catenin pathway. Co-author DOI 10.1016/j.biopha.2020.110126↗
  13. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  14. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  15. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  16. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  17. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  18. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  19. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  20. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Co-author DOI 10.1159/000494547↗
  21. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. First author DOI 10.1186/s13046-018-0740-4↗
  22. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗
  23. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  24. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Co-author DOI 10.3892/or.2018.6696↗
  25. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  26. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  27. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  28. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 25 shared papers, 2016–2025 · strength 2.57
  2. Weikun Qian · 21 shared papers, 2017–2025 · strength 2.32
  3. Zheng Wang · 12 shared papers, 2016–2025 · strength 1.50
  4. Wanxing Duan · 16 shared papers, 2016–2022 · strength 1.27
  5. Zheng Wu · 8 shared papers, 2019–2025 · strength 1.14
  6. Jiguang Ma · 14 shared papers, 2016–2021 · strength 1.07
  7. Zhengdong Jiang · 13 shared papers, 2016–2023 · strength 1.01
  8. Liang Cheng · 13 shared papers, 2017–2019 · strength 0.95
  9. Jie Hao · 4 shared papers, 2023–2025 · strength 0.88
  10. Junyu Cao · 11 shared papers, 2017–2019 · strength 0.80
  11. Xuqi Li · 8 shared papers, 2017–2025 · strength 0.78
  12. Bin Yan · 10 shared papers, 2017–2019 · strength 0.73
  13. Ke Chen · 10 shared papers, 2016–2021 · strength 0.73
  14. Ruiqi Cao · 3 shared papers, 2024–2025 · strength 0.66
  15. Liankang Sun · 9 shared papers, 2016–2019 · strength 0.61
  16. Jiantao Mo · 3 shared papers, 2022–2025 · strength 0.58
  17. Jie Li · 7 shared papers, 2017–2021 · strength 0.55
  18. Ying Xiao · 5 shared papers, 2018–2021 · strength 0.48
  19. Yangyang Yue · 4 shared papers, 2020–2022 · strength 0.46
  20. Shuai Wu · 2 shared papers, 2025 · strength 0.44
  21. Wunai Zhang · 2 shared papers, 2023–2025 · strength 0.37
  22. Zeen Zhu · 2 shared papers, 2022–2025 · strength 0.35
  23. Wei Li · 2 shared papers, 2022–2024 · strength 0.34
  24. Jianjun Lei · 4 shared papers, 2017–2021 · strength 0.31
  25. Liang Han · 3 shared papers, 2018–2022 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.